Aprea Therapeutics (APRE) Price & Analysis

Compare

482 Followers

APRE Stock Chart & Stats

$1.11

-$0.03(-0.72%)

At close: Jan 08 4:00 PM EST

$1.11

-$0.03(-0.72%)

Day’s Range― - ―

52-Week Range$1.08 - $5.00

Previous CloseN/A

Volume2.88K

Average Volume (3M)55.77K

Market Cap

$7.00M

Enterprise Value-$5.52M

Total Cash (Recent Filing)$13.72M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.79

Next Earnings

Mar 26, 2026

EPS Estimate

-0.43

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.47

Shares Outstanding6,310,673

10 Day Avg. Volume84,633

30 Day Avg. Volume55,770

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)0.94

Price to Sales (P/S)12.06

P/FCF Ratio-1.34

Enterprise Value/Market Cap-0.79

Enterprise Value/Revenue-11.31

Enterprise Value/Gross Profit0.88

Enterprise Value/Ebitda0.40

Forecast

1Y Price Target

$10.00

Price Target Upside800.90% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe safety and toxicity profile of Aprea's programs remain favorable, which is crucial for the continuation and advancement of their clinical trials.

Innovation And StrategyAprea acquired Atrin Pharmaceuticals, bringing in current SL assets and a CEO with expertise in the SL space, including demonstration of the importance of the ATR pathway in cancer.

Therapeutic EfficacyAPR-1051 demonstrated stable disease in several patients and is advancing to higher dosing cohorts, showing promising efficacy signals.

Bears Say

Industry ChallengesIssues in the synthetic lethality space, particularly for companies like Repare and Zentalis, cast a shadow over Aprea.

Share Price PerformanceAprea's share price has pulled back to near an all-time low, driven by factors unrelated to the synthetic lethality pipeline.

Aprea Therapeutics News

Aprea Therapeutics reports Q3 EPS (47c) vs. (64) last year

“We are pleased with the continued progress in our development programs, as the emerging data on both of...

21d ago

APRE

Aprea Therapeutics sees cash runway into 4Q26

As of September 30, 2025, the Company reported cash and cash equivalents of $13.7 million compared to $22.8...

21d ago

APRE

Aprea Therapeutics: Promising Advancements in Synthetic Lethality Programs Drive Buy Rating

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Aprea Therapeutics, retaining the price target of...

20d ago

APRE

Aprea Therapeutics Reports Ongoing Financial Challenges

Aprea Therapeutics, Inc. ( ($APRE) ) has released its Q3 earnings. Here is a breakdown of the information...

21d ago

APRE

Aprea Therapeutics Reports Q3 Results and Clinical Updates

The latest announcement is out from Aprea Therapeutics ( ($APRE) ). On November 12, 2025, Aprea Therapeutics reported...

21d ago

APRE

Aprea Therapeutics Advances ATRN-119 Study for Solid Tumors

Aprea Therapeutics, Inc. (($APRE)) announced an update on their ongoing clinical study. Aprea Therapeutics, Inc. is conducting a...

1M ago

APRE

Aprea Therapeutics Advances with Phase 1 Study of APR-1051 in Solid Tumors

Aprea Therapeutics, Inc. (($APRE)) announced an update on their ongoing clinical study. Aprea Therapeutics, Inc. is conducting a...

1M ago

APRE

Aprea Therapeutics Reports Promising Trial Results for APR-1051

The latest update is out from Aprea Therapeutics ( ($APRE) ). On October 24, 2025, Aprea Therapeutics announced...

1M ago

APRE

Aprea Therapeutics provides update from ACESOT-1051 t rial

Aprea Therapeutics (APRE) provided an update on the ongoing Phase 1 ACESOT-1051 study. The latest results show that,...

1M ago

APRE

Aprea Therapeutics: Strategic Advancements and Unique Positioning Drive Buy Recommendation

Aprea Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from...

2M ago

APRE

Aprea Therapeutics Shifts Focus to Combination Therapies

Aprea Therapeutics ( ($APRE) ) has shared an announcement. On October 15, 2025, Aprea Therapeutics announced the recommended...

2M ago

APRE

Aprea Therapeutics establishes RP2D for ATRN-119

Aprea Therapeutics (APRE) announced that it has determined the recommended Phase 2 dose, RP2D, of 1,100 mg once...

2M ago

APRE

Aprea Therapeutics Highlights Progress in Clinical Trials

Aprea Therapeutics ( ($APRE) ) has provided an announcement. On September 8, 2025, Aprea Therapeutics updated its corporate...

3M ago

APRE

Positive Outlook for Aprea Therapeutics: Promising Progress in WEE1i and ATRi Candidates Amidst Challenges

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Aprea Therapeutics. The associated price target...

4M ago

APRE

APRE FAQ

What was Aprea Therapeutics Inc’s price range in the past 12 months?

Aprea Therapeutics Inc lowest stock price was $1.08 and its highest was $5.00 in the past 12 months.

What is Aprea Therapeutics Inc’s market cap?

Aprea Therapeutics Inc’s market cap is $7.00M.

When is Aprea Therapeutics Inc’s upcoming earnings report date?

Aprea Therapeutics Inc’s upcoming earnings report date is Mar 26, 2026 which is in 113 days.

How were Aprea Therapeutics Inc’s earnings last quarter?

Aprea Therapeutics Inc released its earnings results on Nov 12, 2025. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.34 by -$0.13.

Is Aprea Therapeutics Inc overvalued?

According to Wall Street analysts Aprea Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aprea Therapeutics Inc pay dividends?

Aprea Therapeutics Inc does not currently pay dividends.

What is Aprea Therapeutics Inc’s EPS estimate?

Aprea Therapeutics Inc’s EPS estimate is -0.43.

How many shares outstanding does Aprea Therapeutics Inc have?

Aprea Therapeutics Inc has 6,310,673 shares outstanding.

What happened to Aprea Therapeutics Inc’s price movement after its last earnings report?

Aprea Therapeutics Inc reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.34. Following the earnings report the stock price went down -4.545%.

Which hedge fund is a major shareholder of Aprea Therapeutics Inc?

Currently, no hedge funds are holding shares in APRE

Company Description

Aprea Therapeutics Inc

Aprea Therapeutics (APRE) is a biotechnology company focused on developing and commercializing novel cancer therapeutics. The company is primarily engaged in the discovery and development of small molecule therapies that reactivate mutant tumor suppressor protein p53, which is often inactivated in a variety of cancers. Aprea's core product pipeline includes drug candidates for the treatment of hematologic malignancies and solid tumors, leveraging its proprietary technology to address unmet medical needs in oncology.

Aprea Therapeutics (APRE) Earnings & Revenues

Historic Earnings Reports

APRE Stock 12 Month Forecast

Average Price Target

$10.00

▲(800.90% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.4,2.0615384615384613,2.723076923076923,3.3846153846153846,4.046153846153846,4.707692307692307,5.36923076923077,6.030769230769231,6.692307692307692,7.353846153846154,8.015384615384615,8.676923076923076,9.338461538461539,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.4,2.0615384615384613,2.723076923076923,3.3846153846153846,4.046153846153846,4.707692307692307,5.36923076923077,6.030769230769231,6.692307692307692,7.353846153846154,8.015384615384615,8.676923076923076,9.338461538461539,{"y":10,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.4,2.0615384615384613,2.723076923076923,3.3846153846153846,4.046153846153846,4.707692307692307,5.36923076923077,6.030769230769231,6.692307692307692,7.353846153846154,8.015384615384615,8.676923076923076,9.338461538461539,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.25,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.77,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.92,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >